ARS Pharmaceuticals, Inc. (SPRY) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$170.87M | -1361.2% |
| 2024 | $13.55M | +122.9% |
| 2023 | -$59.27M | -47.9% |
| 2022 | -$40.08M | -128.2% |
| 2021 | -$17.56M | +43.7% |
| 2020 | -$31.20M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$170.87M | -1361.2% |
| 2024 | $13.55M | +122.9% |
| 2023 | -$59.27M | -47.9% |
| 2022 | -$40.08M | -128.2% |
| 2021 | -$17.56M | +43.7% |
| 2020 | -$31.20M | — |